Legal & General Group
ACTU

Legal & General Group’s Actuate Therapeutics ACTU Stock Holding History

Legal & General Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.03K Sell
1,107
-172
-13% -$713 ﹤0.01% 3326
2025
Q4 		$7.83K Buy
1,279
+571
+81% +$3.92K ﹤0.01% 3295
2025
Q3 		$4.74K Hold
708
– – ﹤0.01% 3368
2025
Q2 		$4.33K Buy
+708
New +$6.19K ﹤0.01% 3393

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's ACTU Position: Q1 2026 in Review

Legal & General Group reduced its Actuate Therapeutics (ACTU) stake by 13% in Q1 2026, selling an estimated $713 and leaving 1,107 shares worth $3.03K. The position accounts for ﹤0.01% of the portfolio, ranked #3326.

Legal & General Group first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. The position peaked at $7.83K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Legal & General Group held 1,107 shares of Actuate Therapeutics worth $3.03K as of Q1 2026.
  • Legal & General Group sold 172 Actuate Therapeutics shares in Q1 2026, an estimated $713.
  • Actuate Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3326 holding.
  • Legal & General Group first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Legal & General Group's Actuate Therapeutics position peaked at $7.83K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.